Answers are grounded in this paper and cite their sources.
Randomized trial investigates efficacy of BELL-001 for insomnia, suggesting a novel therapeutic option.
Introduction Insomnia affects 10-15% of adults worldwide. While pharmacotherapy offers rapid symptom relief, concerns about dependence limit its use. Prescription digital therapeutics (PDTs) have emerged as scalable alternatives, yet existing PDTs largely replicate CBT-I principles and face similar adherence challenges inherent to behavioral interventions requiring sustained patient engagement. BELL-001 represents the first PDTs designed to translate the mechanism of hypnotics rather than behavioral modification. Using auditory stimulation, BELL-001 induces acute autonomic downregulation within the first 30 minutes of use, targeting hyperarousal through real-time biosignal capturing and dynamic acoustic feedback. This pharmacomimetic approach enables immediate effects without multi-week behavioral conditioning. The SERENE trial (Sleep Efficacy Randomized Evaluation of a digital thErapeutic for iNsomnia) was designed to rigorously evaluate the short-term efficacy and safety of BELL-001 in adults with insomnia. Methods SERENE is a multicenter, prospective, randomized, double-blind, sham-controlled, superiority trial. A minimum of 114 participants aged 19-75 years diagnosed with insomnia according to ICD-11 criteria and with an Insomnia Severity Index (ISI) score ≥15 will be enrolled from six medical centers in the Republic of Korea. Eligible participants will be randomized 1:1 to the BELL-001 or sham group. The primary endpoint is the change in ISI score from baseline to 4 weeks. Secondary endpoints include proportion of clinical responders (≥6-point ISI reduction), subjective sleep onset latency and wake after sleep onset from sleep diaries, and validated questionnaires assessing sleepiness, fatigue, depression, anxiety, quality of life, and work productivity. Treatment-emergent adverse events will be evaluated for safety analysis. Results The trial has received Korean Ministry of Food and Drug Safety (MFDS; K-FDA) approval in the Republic of Korea. Conclusion SERENE trial is the first Phase 3 evaluation of a pharmacomimetic prescription digital therapeutic designed to translate hypnotics mechanism. This study will provide evidence on whether BELL-001 can establish a neuromodulation-based PDTs delivering rapid efficacy with a favorable safety profile, offering clinicians a safe and effective treatment option for patients with insomnia disorder. Support (if any) BELL Therapeutics Inc.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: